Kinase Inhibitor | Major Enzyme(s) Involved in Metabolism | Minor Enzyme(s) Involved in Metabolism |
---|---|---|
Afatinib | Nonenzymatic | FMO3, CYP3A4 |
Alectinib | CYP3A4 | |
Axitinib | CYP3A4/5 | CYP1A2, CYP2C19, UGT1A1 |
Bosutinib | CYP3A4 | |
Cabozantinib | CYP3A4 | |
Ceritinib | CYP3A, CYP2C9 | |
Cobimetinib | CYP3A, UGT2B7 | |
Crizotinib | CYP3A4/5 | |
Dabrafenib | CYP2C8, CYP3A4 | |
Dasatinib | CYP3A4 | FMO3, UGT |
Erlotinib | CYP3A4 | CYP1A2 |
Gefitinib | CYP3A4 | |
Ibrutinib | CYP3A | CYP2D6 |
Idelalisib | Aldehyde oxidase, CYP3A | |
Imatinib | CYP3A4 | CYP1A2, CYP2D6, CYP2C9, CYP2C19, |
Lapatinib | CYP3A4, CYP3A5 | CYP2C19, CYP2C8 |
Lenvatinib | CYP3A, aldehyde oxidase | |
Nilotinib | CYP3A4 | |
Nintedanib | Esterases, UGT 1A1, UGT 1A7, UGT 1A8, UGT 1A10 | CYP3A4 |
Osimertinib | CYP3A | |
Palbociclib | CYP3A, SULT2A1 | |
Pazopanib | CYP3A4 | CYP1A2, CYP2C8 |
Ponatinib | CYP3A4 | CYP2C8, CYP2D6, CYP3A5, esterases and/or amidases |
Regorafenib | CYP3A4, UGT1A9 | |
Ruxolitinib | CYP3A4 | |
Sorafenib | CYP3A4, UGT1A9 | |
Sunitinib | CYP3A4 | |
Tofacitinib | CYP3A4 | CYP2C19 |
Trametiniba | Deacetylation, mono-oxygenation, and/or glucuronidation | CYP3A4 |
Vandetanib | CYP3A4 | FMO1, FMO3 |
Vemurafenib | CYP3A4 |
↵a Deacetylated product metabolized by CYP3A4.